DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective close of business March 12, 2021. Mr. Dolan will replace current CFO Gary Sender, who is retiring from Nabriva. Mr. Sender will serve as a consultant for Nabriva at least through the remainder of 2021 to support Mr. Dolan’s transition into the CFO role.

See the rest here:
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh